同宜医药宣布已与 MultiValent Biotherapies, Inc.（以下简称“MultiValent”）就治疗前列腺癌的多肽类偶联药物 CBP-1018 达成独家许可协议。
Suzhou, China, February 21, 2025 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration...
October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
On June 24, 2024, local time, the U.S. Food and Drug Administration (FDA) notified the approval of Orphan Drug Designation (ODD) f...
ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention
The American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held from May 31 to June 4 in Chicago, USA. At this year...
Recently, Coherent Biopharma disclosed the latest preclinical research progress of CBP-8008, at the 2024 American Association...